BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
August 01 2019 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company developing novel cell therapies for unmet
medical needs, today announced that it will report its second
quarter 2019 financial and operating results on Thursday, August
8th, 2019, following the close of the U.S. financial markets.
BioTime management will also host a conference call and webcast on
Thursday, August 8th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m.
Pacific Time to discuss its second quarter 2019 financial results
and to provide a business update.
Interested parties may access the conference call by dialing
(866) 888-8633 from the U.S. and Canada and (636) 812-6629 from
elsewhere outside the U.S. and Canada and should request the
“BioTime Inc. Call”. A live webcast of the conference call will be
available online in the Investors section of BioTime’s website. A
replay of the webcast will be available on BioTime’s website for 30
days and a telephone replay will be available through August 15th,
2019, by dialing (855) 859-2056 from the U.S. and Canada and (404)
537-3406 from elsewhere outside the U.S. and Canada and entering
conference ID number 8783397.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company developing
novel cell therapies for unmet medical needs. BioTime’s programs
are based on its proprietary cell-based therapy platform and
associated development and manufacturing capabilities. With this
platform BioTime develops and manufactures specialized,
terminally-differentiated human cells from its pluripotent and
progenitor cell starting materials. These differentiated cells are
developed either to replace or support cells that are dysfunctional
or absent due to degenerative disease or traumatic injury or
administered as a means of helping the body mount an effective
immune response to cancer. BioTime’s clinical assets include (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
I/IIa development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase
I/IIa development for the treatment of acute spinal cord injuries;
and (iii) VAC2, an allogeneic cancer immunotherapy of
antigen-presenting dendritic cells currently in Phase I development
for the treatment of non-small cell lung cancer. For more
information, please visit www.biotimeinc.com or follow the Company
on Twitter @BioTimeBTX. BioTime announced that it is changing its
name to Lineage Cell Therapeutics, effective August 12, 2019.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190801005044/en/
BioTime Inc. IR Ioana C. Hone (ir@biotimeinc.com) (510)
871-4188
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024